Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
August 17, 2021 09:25 ET | Lixte Biotechnology Holdings, Inc.
A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) --...
AIR_Logo_cropped copy.jpg
Applied Impact Robotics, Developers of an Automated Inspection Solution for Capital Intensive Infrastructure, Appoints Jim Nyquist to its Board of Directors as an Independent Director
July 28, 2021 08:00 ET | Applied Impact Robotics
Sterling, Virginia, July 28, 2021 (GLOBE NEWSWIRE) -- Applied Impact Robotics (AIR), developers of a solution for the in-service inspection and maintenance of Aboveground Storage Tanks (ASTs),...
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
May 04, 2021 16:30 ET | Lixte Biotechnology Holdings, Inc.
Multiple pre-clinical studies indicate that Lixte’s lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments EAST SETAUKET, NY, May 04, 2021 (GLOBE...
Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14
April 28, 2021 09:35 ET | Lixte Biotechnology Holdings, Inc.
Lixte’s pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100 EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc....